Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
49.33
+2.49 (5.32%)
At close: Jun 25, 2025, 4:00 PM
49.43
+0.10 (0.20%)
After-hours: Jun 25, 2025, 7:47 PM EDT
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Cidara Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $49.44, which forecasts a 0.22% increase in the stock price over the next year. The lowest target is $35 and the highest is $75.
Price Target: $49.44 (+0.22%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 6 |
Buy | 3 | 3 | 4 | 4 | 4 | 5 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 8 | 8 | 8 | 11 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Maintains $35 → $75 | Buy | Maintains | $35 → $75 | +52.04% | Jun 24, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $50 → $68 | Strong Buy | Maintains | $50 → $68 | +37.85% | Jun 24, 2025 |
WBB Securities | WBB Securities | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | -8.78% | Jun 23, 2025 |
Needham | Needham | Strong Buy Maintains $36 → $54 | Strong Buy | Maintains | $36 → $54 | +9.47% | Jun 23, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $41 | Strong Buy | Initiates | $41 | -16.89% | Jun 18, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.28M
Revenue Next Year
n/a
EPS This Year
-7.53
from -26.75
EPS Next Year
-8.45
from -7.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -5.86 | -5.57 | -4.49 | ||
Avg | -7.53 | -8.45 | -8.25 | ||
Low | -9.12 | -10.28 | -9.83 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.